A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Journal of Visualized Experiments · 2024
DOI: 10.3791/64401 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2024. Written by Ziming Cao and 4 co-authors. Institution: Department of Immunology, School of Medicine, UConn Health. Major MEDLINE topics: CD18 Antigens, Cell Adhesion Molecules. 56 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS.
Abstract (original language)
This protocol aims to establish a method for identifying small molecular antagonists of β2 integrin activation, utilizing conformational-change-reporting antibodies and high-throughput flow cytometry. The method can also serve as a guide for other antibody-based high-throughput screening methods. β2 integrins are leukocyte-specific adhesion molecules that are crucial in immune responses. Neutrophils rely on integrin activation to exit the bloodstream, not only to fight infections but also to be involved in multiple inflammatory diseases. Controlling β2 integrin activation presents a viable approach for treating neutrophil-associated inflammatory diseases. In this protocol, a monoclonal antibody, mAb24, which specifically binds to the high-affinity headpiece of β2 integrins, is utilized to quantify β2 integrin activation on isolated primary human neutrophils. N-formylmethionyl-leucyl-phenylalanine (fMLP) is used as a stimulus to activate neutrophil β2 integrins. A high-throughput flow cytometer capable of automatically running 384-well plate samples was used in this study. The effects of 320 chemicals on β2 integrin inhibition are assessed within 3 h. Molecules that directly target β2 integrins or target molecules in the G protein-coupled receptor-initiated integrin inside-out activation signaling pathway can be identified through this approach.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Immunology, School of Medicine, UConn Health.
- Center for Molecular Discovery, University of New Mexico Health Sciences Center.
- Center for Molecular Discovery, University of New Mexico Health Sciences Center; Comprehensive Cancer Center, University of New Mexico Health Sciences Center; Department of Pathology, University of New Mexico Health Sci…
- Comprehensive Cancer Center, University of New Mexico Health Sciences Center; Department of Pathology, University of New Mexico Health Sciences Center.
- Department of Immunology, School of Medicine, UConn Health; zfan@uchc.edu.
Funding
- NHLBI NIH HHS
Cite
APA
Cao, Z., Garcia, M. J., Sklar, L. A., Wandinger-Ness, A., & Fan, Z. (2024). A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs. Journal of Visualized Experiments. https://doi.org/10.3791/64401
Vancouver
Cao Z, Garcia MJ, Sklar LA, Wandinger-Ness A, Fan Z. A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs. Journal of Visualized Experiments. 2024. doi:10.3791/64401
BibTeX
@article{Cao2024,
author = {Cao, Ziming and Garcia, Matthew J and Sklar, Larry A and Wandinger-Ness, Angela and Fan, Zhichao},
title = {A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs},
journal = {Journal of Visualized Experiments},
year = {2024},
doi = {10.3791/64401}
}
EUVIMED